Also inform your GP as soon as possible
This mechanism counteracts the effects of ghrelin, a hormone that increases appetite and promotes fat storage
Patients most likely to benefit from GLP-1 therapy for fat reduction include those with a BMI of 30 kg/m or greater, or a BMI of 27 kg/m or greater with weight-related conditions such as hypertension, dyslipidemia, obstructive sleep apnea, or cardiovascular disease
However, sweating as a reaction to feeling cold during pregnancy could indicate an underlying condition and should be discussed with your doctor
These results represent a pivotal moment for people with obesity and the global scientific community as we look ahead to a new era of managing obesity and potentially reducing cardiovascular risks with semaglutide 2.4 mg. In the trial, semaglutide 2.4 mg appeared to have a safe and well-tolerated profile in line with previous semaglutide 2.4 mg trials
It's important to share your medical history with your healthcare provider, so they can suggest a safe and effective option for you
